[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Benjamín Gonzalo Rodríguez Méndez\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641148",false,"NCT07656818","Non-Thermal Plasma to Reduce Recurrence in Chronic Subdural Hematoma","Application of Non-Thermal Plasma in the Surgical Bed of Chronic Subdural Hematoma to Reduce the Post-Drainage Recurrence Rate: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥ 18 years of age\n* Diagnosis of symptomatic chronic subdural hematoma (cSDH) requiring surgical drainage (burr hole drainage or craniotomy)\n* Ability to provide written informed consent (or consent from legal representative if patient is incapacitated)\n\nExclusion Criteria:\n\n* Pure acute or subacute subdural hematoma\n* Uncontrolled coagulopathy or bleeding disorder\n* History of intracranial aneurysm or prior cerebrovascular event with residual deficit\n* Presence of active intracranial metallic implants or electronic devices (e.g., programmable shunt, cardiac pacemaker, deep brain stimulator) in the head region\n* Pregnancy or lactation\n* Participation in another interventional clinical trial within 30 days prior to screening","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this randomized controlled trial is to evaluate whether the adjuvant application of non-thermal plasma (NTP) during standard surgical drainage of chronic subdural hematoma (cSDH) can reduce the recurrence rate at 6 months. The main questions it aims to answer are:\n\n* Does NTP application significantly lower the radiological and clinical recurrence rate of cSDH compared to surgery alone?\n* Is NTP safe when applied to the subdural space and surgical wound bed?\n* Does NTP improve functional outcomes and time to hematoma resolution?\n\nParticipants will be randomly assigned to one of two groups:\n\n* Experimental group (n = 20): Standard burr hole drainage or craniotomy plus intraoperative NTP application over the exposed dura mater, the residual membrane, soft tissue layers, and the skin incision.\n* Control group (n = 20): Standard surgical drainage alone (no NTP).\n\nFollow-up includes clinical assessments and computed tomography (CT) scans at 1 week, 3 months, and 6 months post-surgery. The primary outcome is recurrence (symptomatic reaccumulation requiring re-intervention or ≥50% volume increase on CT).",[25,26,27,28],"Chronic Subdural Hematoma","Subdural Hematoma","Recurrence","Postoperative Complications",[30,31,32,33,34,35],"Non-thermal plasma","Cold plasma","Chronic subdural hematoma","Neurosurgery","Recurrence prevention","Wound healing","RECRUITING","2026-06-16",{"date":39,"type":40},"2026-06-18","ACTUAL",{"date":42,"type":40},"2026-03-02",{"date":44,"type":19},"2027-04-30",{"name":46,"class":47},"Benjamín Gonzalo Rodríguez Méndez","OTHER",1,{"id":50,"slug":4,"hasResults":10,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100634554","NCT07541196","PAW-Hydrogel for Chronic Wound Healing","Efficacy and Safety of a Carbopol® 940 Hydrogel Functionalized With Plasma-Activated Water (PAW) in the Treatment of Chronic Wounds: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Diagnosis of chronic wound (diabetic foot ulcer Wagner grade 1-2, pressure injury grade I-III, dehiscent surgical wound, venous or arterial ulcer) with duration \\> 3 months.\n* Wound surface area between 2 cm² and 20 cm².\n* For diabetic patients: HbA1c \\\u003C 9% (stable metabolic control).\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Clinical or radiological evidence of osteomyelitis (Wagner grade \\> 3).\n* Severe arterial insufficiency (ankle-brachial index \\\u003C 0.5).\n* Use of systemic corticosteroids or immunosuppressants.\n* Pregnancy or lactation.\n* Known autoimmune skin disease (e.g., pemphigus, epidermolysis bullosa).\n* Active malignancy or undergoing chemotherapy\u002Fradiotherapy.\n* Participation in another interventional clinical trial within 30 days prior to screening.",{"count":56,"type":19},50,[22],"The goal of this randomized controlled trial is to evaluate the efficacy and safety of a novel hydrogel made of Carbopol® 940 functionalized with Plasma-Activated Water (PAW) in patients with chronic wounds (diabetic foot ulcers, pressure injuries, dehiscent wounds, arterial and venous ulcers). The main questions it aims to answer are:\n\n* Does PAW-hydrogel accelerate wound closure (reduction in surface area) compared to standard advanced wound care?\n* Does PAW-hydrogel reduce bacterial load in the wound bed?\n* Is PAW-hydrogel safe and well-tolerated (local adverse events, pain)?\n\nParticipants will be randomly assigned to one of two groups:\n\n* Experimental group: Topical application of PAW-hydrogel (Carbopol® 940 neutralized to pH 5.5, loaded with reactive oxygen and nitrogen species from plasma activation) 2-3 times per week.\n* Control group: Standard advanced wound care (cleaning, debridement, conventional dressings).\n\nWound area (planimetry), bacterial load (semi-quantitative cultures), pain (Visual Analog Scale), tissue quality (Bates-Jensen scale), and adverse events will be assessed over a 12-week follow-up period.",[60,61,62,63,64,65],"Diabetic Foot Ulcer (DFU)","Pressure Ulcer (PU)","Wound Dehiscence","Venous Leg Ulcer","Arterial Ulcer","Chronic Wound",[67,68,69,70,71,72,73],"Plasma-Activated Water","PAW","Hydrogel","Chronic Wounds","Diabetic Foot","Wound Healing","RONS","2026-04-14",{"date":76,"type":40},"2026-04-21",{"date":78,"type":19},"2026-04-20",{"date":80,"type":19},"2027-07-30",{"name":46,"class":47},""]